SSC Medical Ltd 13435407 false 2025-04-01 2026-03-31 2026-03-31 The principal activity of the company is a pharmacy Digita Accounts Production Advanced 6.30.9574.0 true 13435407 2025-04-01 2026-03-31 13435407 2026-03-31 13435407 core:RetainedEarningsAccumulatedLosses 2026-03-31 13435407 core:ShareCapital 2026-03-31 13435407 core:CurrentFinancialInstruments 2026-03-31 13435407 core:CurrentFinancialInstruments core:WithinOneYear 2026-03-31 13435407 core:Goodwill 2026-03-31 13435407 core:OtherResidualIntangibleAssets 2026-03-31 13435407 core:OtherPropertyPlantEquipment 2026-03-31 13435407 bus:SmallEntities 2025-04-01 2026-03-31 13435407 bus:AuditExemptWithAccountantsReport 2025-04-01 2026-03-31 13435407 bus:FilletedAccounts 2025-04-01 2026-03-31 13435407 bus:SmallCompaniesRegimeForAccounts 2025-04-01 2026-03-31 13435407 bus:RegisteredOffice 2025-04-01 2026-03-31 13435407 bus:Director1 2025-04-01 2026-03-31 13435407 bus:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 13435407 bus:Agent1 2025-04-01 2026-03-31 13435407 core:Goodwill 2025-04-01 2026-03-31 13435407 core:OtherResidualIntangibleAssets 2025-04-01 2026-03-31 13435407 core:OtherPropertyPlantEquipment 2025-04-01 2026-03-31 13435407 core:PlantMachinery 2025-04-01 2026-03-31 13435407 countries:EnglandWales 2025-04-01 2026-03-31 13435407 2025-03-31 13435407 core:Goodwill 2025-03-31 13435407 core:OtherResidualIntangibleAssets 2025-03-31 13435407 core:OtherPropertyPlantEquipment 2025-03-31 13435407 2024-04-01 2025-03-31 13435407 2025-03-31 13435407 core:RetainedEarningsAccumulatedLosses 2025-03-31 13435407 core:ShareCapital 2025-03-31 13435407 core:CurrentFinancialInstruments 2025-03-31 13435407 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 13435407 core:Goodwill 2025-03-31 13435407 core:OtherResidualIntangibleAssets 2025-03-31 13435407 core:OtherPropertyPlantEquipment 2025-03-31 iso4217:GBP xbrli:pure

Registration number: 13435407

SSC Medical Ltd

Unaudited Financial Statements

31 March 2026

image-name

 

SSC Medical Ltd

Contents

Accountants' Report

1

Balance Sheet

2

Notes to the Unaudited Financial Statements

4

 

Chartered Accountants' Report to the Director on the Preparation of the Unaudited Statutory Accounts of
SSC Medical Ltd
for the Year Ended 31 March 2026

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of SSC Medical Ltd for the year ended 31 March 2026 as set out on pages 2 to 9 from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at http://www.icaew.com/regulation.

This report is made solely to the Board of Directors of SSC Medical Ltd, as a body, in accordance with the terms of our engagement letter dated 19 June 2025. Our work has been undertaken solely to prepare for your approval the accounts of SSC Medical Ltd and state those matters that we have agreed to state to the Board of Directors of SSC Medical Ltd, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than SSC Medical Ltd and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that SSC Medical Ltd has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and loss of SSC Medical Ltd. You consider that SSC Medical Ltd is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the accounts of SSC Medical Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.



Dodd & Co Limited
Chartered Accountants
Clint Mill
Cornmarket
PENRITH
CA11 7HW

7 July 2026

 

SSC Medical Ltd

(Registration number: 13435407)
Balance Sheet as at 31 March 2026

Note

2026
£

2025
£

Fixed assets

 

Intangible assets

4

530,428

622,677

Tangible assets

5

25,329

22,988

 

555,757

645,665

Current assets

 

Stocks

119,606

116,047

Debtors

6

125,741

115,447

Cash at bank and in hand

 

91,984

86,533

 

337,331

318,027

Creditors: Amounts falling due within one year

7

(1,123,939)

(1,127,393)

Net current liabilities

 

(786,608)

(809,366)

Total assets less current liabilities

 

(230,851)

(163,701)

Provisions for liabilities

(7,069)

(6,612)

Net liabilities

 

(237,920)

(170,313)

Capital and reserves

 

Allotted, called up and fully paid share capital

100

100

Profit and loss account

(238,020)

(170,413)

Total equity

 

(237,920)

(170,313)

 

SSC Medical Ltd

(Registration number: 13435407)
Balance Sheet as at 31 March 2026 (continued)

For the financial year ending 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 7 July 2026
 

.........................................

S Y Wong

Director

 

SSC Medical Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Clint Mill
Cornmarket
PENRITH
CA11 7HW

The principal place of business is:
Brampton Pharmacy
Market Place
BRAMPTON
CA8 1RW

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The company has net liabilities at 31 March 2026 and to meet its day to day working capital requirements by utilising an intercompany loan with its parent company, which is repayable upon demand. On the basis of this support, the director considers it appropriate to prepare the financial statements on the going concern basis.

However, should the company not have the support of its parent, and therefore be unable to continue trading, adjustments would have to be made to reduce the value of assets to their recoverable amounts, to provide for any further liabilities which might arise, and to reclassify fixed assets and long term liabilities as current assets and current liabilities.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when the amount of revenue can be reliably measured; it is probable that future economic benefits will flow to the entity; and specific criteria have been met for each of the company's activities.

 

SSC Medical Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026 (continued)

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Plant and equipment

25% reducing balance basis

Goodwill

Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the company’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is amortised over its useful life, which shall not exceed ten years if a reliable estimate of the useful life cannot be made.

Intangible assets

Separately acquired trademarks and licences are shown at historical cost. Trademarks, licences (including software) and customer-related intangible assets acquired in a business combination are recognised at fair value at the acquisition date. Trademarks, licences and customer-related intangible assets have a finite useful life and are carried at cost less accumulated amortisation and any accumulated impairment losses.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class

Amortisation method and rate

Goodwill

10 years straight line basis

Other intangible assets

10 years straight line basis

 

SSC Medical Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026 (continued)

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for the sale of goods or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method where due after more than one year.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

 

SSC Medical Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026 (continued)

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 9 (2025 - 8).

 

SSC Medical Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026 (continued)

4

Intangible assets

Goodwill
 £

Other intangible assets
 £

Total
£

Cost or valuation

At 1 April 2025

917,359

5,125

922,484

At 31 March 2026

917,359

5,125

922,484

Amortisation

At 1 April 2025

298,142

1,665

299,807

Amortisation charge

91,736

513

92,249

At 31 March 2026

389,878

2,178

392,056

Carrying amount

At 31 March 2026

527,481

2,947

530,428

At 31 March 2025

619,217

3,460

622,677

5

Tangible assets

Plant and equipment
 £

Total
£

Cost or valuation

At 1 April 2025

55,363

55,363

Additions

10,784

10,784

At 31 March 2026

66,147

66,147

Depreciation

At 1 April 2025

32,375

32,375

Charge for the year

8,443

8,443

At 31 March 2026

40,818

40,818

Carrying amount

At 31 March 2026

25,329

25,329

At 31 March 2025

22,988

22,988

 

SSC Medical Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026 (continued)

6

Debtors

2026
£

2025
£

Trade debtors

95,540

89,727

Other debtors

30,201

25,720

125,741

115,447

7

Creditors

Note

2026
£

2025
£

Due within one year

 

Loans and borrowings

8

427

-

Trade creditors

 

118,443

132,097

Amounts owed to group undertakings and undertakings in which the company has a participating interest

 

993,465

988,313

Corporation tax liability

 

6,958

2,415

Other creditors

 

4,646

4,568

 

1,123,939

1,127,393

8

Loans and borrowings

2026
£

2025
£

Current loans and borrowings

Other borrowings

427

-

9

Financial commitments, guarantees and contingencies

Amounts not provided for in the balance sheet

The total amount of financial commitments not included in the balance sheet is £193,500 (2025 - £211,500). This is in relation to a property lease expiring in January 2037.

The total amount of guarantees not included in the balance sheet is £1,725,402 (2025 - £1,811,195). Barclays Bank PLC hold fixed and floating charges in respect of the company's assets. The security relates to a cross company guarantee against bank loans obtained by H & W Pharma Limited (the parent company).